COTY
21.4.2021 10:02:12 CEST | Business Wire | Press release
Coty Inc. (NYSE: COTY), one of the world’s leading beauty companies and the global leader in fragrances, today announced that Lancaster has become the first ever sun care brand awarded the prestigious C2C Certified Material Health Certificate at the Silver level from the Cradle to Cradle Products Innovation Institute.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210421005237/en/
The award indicates that 100% of the ingredients in Lancaster Sun Sensitive collection –Lancaster’s first clean and vegan range, and its most environmentally friendly yet - meet the Institute’s strict criteria. In addition to recognizing the sustainable innovation behind the collection, the Certification serves as the foundation for further improving the sustainability and product safety of sun care products over time.
Lancaster Sun Sensitive collection provides broad sun protection* targeting 100% of sun spectrum through a clean, minimalistic** vegan formula providing even sensitive skin with a delicate golden glow, preserved from redness and discomfort. The products also feature an ocean friendly UV filter system*** - all delivered in eco-designed packaging.****
Sue Y. Nabi, Chief Executive Officer at Coty , said: “Sustainability is the ultimate driver of innovation and brands like Lancaster are creating outstanding products that are truly clean and green. Today’s consumer rightly expects that their favorite products also deliver when it comes to environmental performance. It’s our approach to product innovation that sets Coty apart and these industry firsts reflect the expertise of our teams and our brands.”
The C2C Certified Material Health Certificate by the Cradle to Cradle Products Innovation Institute offers a solution to growing industry and consumer interest in knowing more about the chemicals used in products across their supply chains and avoiding chemicals of concern. By using the rigorous, globally recognized material health assessment methodology of the Cradle to Cradle Certified Product Standard, the Material Health Certificate provides manufacturers with a trusted means of assessing, optimizing and verifying their product chemistries for safety and the environment. A C2C Certified Material Health Certificate is awarded to products that meet the Material Health requirements of the multi-attribute Cradle to Cradle Certified™ Product Standard. The certificate is valid for two years.
“Beyond leading the way in sun care with the first C2C Certified Material Health Certificate in the category, Coty is also paving the way towards greater product safety, transparency and innovation throughout the beauty industry ,” said Dr. Christina Raab, Vice President of Strategy and Development for the Cradle to Cradle Products Innovation Institute.
Laure Calvel, VP Global Marketing at Lancaster , said: “Receiving the Cradle to Cradle Products Innovation Institute’s Silver Level Material Health Certificate for our Sun Sensitive range is another positive step in demonstrating the safe use of materials that are circular and responsible in our products. We have a framework for improving the sustainability of all the products in our portfolio and very ambitious plans over the coming years.”
Product innovation is a crucial element of Coty’s journey to becoming a more circular business and creating a more sustainable and inclusive world – as set out in its Beauty That Lasts’ strategy. Today’s announcement builds on the success of Calvin Klein’s first clean and environmentally conscious fragrance, CK EVERYONE, which achieved a Material Health Certificate at the Silver level from the Cradle to Cradle Products Innovation Institute in April 2020.
Last month, Coty announced a partnership with LanzaTech to introduce sustainable ethanol made from captured-carbon emissions into its fragrance products. LanzaTech captures industrial emissions and processes the waste gases into a new, more sustainable source of ethanol that is suitable for use in fragrances. Coty has set the goal of having the majority of its fragrance portfolio using ethanol sourced from carbon-capture by 2023.
* No sunscreen product can provide full protection against sun’s rays. Overexposure to the sun is a dangerous health risk.
** Formulas contain on average 40% fewer ingredients than previous range/competitors.
*** In vitro test method established with the University of Nice Institute to assess the potential impact of a sunscreen product on cnidarian cells.
**** Tubes/bottles contain at minimum 50% post-consumer recycled materials.
About Coty Inc.
Coty is one of the world’s largest beauty companies with an iconic portfolio of brands across fragrance, color cosmetics, and skin and body care. Coty is the global leader in fragrance and number three in color cosmetics. Coty’s products are sold in over 150 countries around the world. Coty and its brands are committed to a range of social causes as well as seeking to minimize its impact on the environment. For additional information about Coty Inc., please visit www.coty.com .
About the Cradle to Cradle Products Innovation Institute
The Cradle to Cradle Products Innovation Institute is dedicated to powering innovation for the circular economy through products that have a positive impact on people and planet. Through the Cradle to Cradle Certified® Products Program, the Institute sets the global standard for products that are safe, circular and made responsibly. Cradle to Cradle Certified is used by many future-focused designers, brands, retailers and manufacturers across the value chain to innovate and optimize materials and products according to the world’s most advanced science-based measures for material health, product circularity, renewable energy and climate, water and soil stewardship, and social fairness. The Institute also powers the global shift to a circular economy through partnerships and collaborative initiatives that equip businesses, governments and other stakeholders with the technical solutions and knowledge they need to innovate the way products are designed and made. For more information about the Institute, visit c2ccertified.org. C2C Certified Material Health Certificate™ is a word mark licensed by the Cradle to Cradle Products Innovation Institute.
About Lancaster SUN SENSITIVE
Lancaster’s broadest sun protection respects the most sensitive skin’s needs:
- Provides optimal protection with Full Light Technology, which targets 100% of sun spectrum (1) (UVB, UVA, Visible Light and Infrared rays).
- Gives a luminous and long-lasting tan which develops gradually thanks to the exclusive natural origin Tan Activator Complex, which stimulates the natural tanning process for a never-ending summer.
- Helps reduce redness and the feeling of discomfort while protecting sensitive skin from sun damage, thanks to the new natural origin Sunsicalm complex.
- Respects marine life, with an ocean friendly UV filter system and water-resistant formulas, while being respectful for the skin with minimalistic (2), vegan formulas, all in eco-designed packaging (3).
- Provides ultra-sensorial and lightweight textures yet clean, that penetrates easily without leaving white traces with a transparent finish after application and a clean labelled fragrance.
- For children, a convenient face and body spray that meets all their needs (anti-sand, wet skin application, tearless formula, water resistant and fragrance-free).
- No sunscreen product can provide full protection against sun’s rays. Overexposure to the sun is a dangerous health risk.
- Formulas contain on average 40% fewer ingredients than previous range/competitors.
- Tubes/bottles contain at minimum 50% post-consumer recycled materials.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005237/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
